Retrospective Study
Copyright ©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 1097-1106
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1097
Table 4 Treatments received by patients with invasive breast tumours (n = 5523)
< 40 yr (n = 706) n (%)40 yr (n = 4817) n (%)P value
Surgery
Breast conserving surgery324 (46.1)1638 (34.3)χ2 = 36.921, bP < 0.001
Mastectomy379 (53.9)3135 (65.7)
Reconstruction
Yes135 (35.7)367 (11.7)χ2 = 158.189, bP < 0.001
No243 (64.3)2762 (88.3)
Nodal Surgery
Sentinel node biopsy (SNB)222 (32.2)1351 (28.7)χ2 = 8.496, aP = 0.014
Axillary dissection (AD)336 (48.7)2572 (54.6)
SNB+AD132 (19.1)787 (16.7)
Chemotherapy
Stage I151 (59.2)633 (39.7)χ2 = 34.433, bP < 0.001
Stage IIA210 (88.6)1291 (83.8)χ2 = 3.572, P = 0.067
Stage IIB97 (100)631 (91.1)χ2 = 9.417, bP < 0.001
Stage III72 (98.6)664 (93.7)NA1
Stage IV8 (100)69(89.6)NA1
Radiotherapy (overall)
All patients496 (72)3106 (66.2)χ2 = 9.189, bP = 0.002
BCS patients306 (96.2)1522 (95.4)χ2 = 0.460, P = 0.556
MTX patients190 (51.6)1564 (51.2)χ2 = 0.027, P = 0.912
Irradiated regions (overall)
Breast ± regional lymph nodes187 (60.1)998 (46)χ2 = 21.859, bP < 0.001
Chest wall ± regional lymph nodes124 (39.9)1173 (54)
Endocrine therapy477 (68.7)3496 (74.2)χ2 = 9.206, bP = 0.003
Targeted therapy59 (8.6)339 (7.2)χ2 = 1.682, P = 0.211